These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9500988)

  • 21. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
    Schang LM; Phillips J; Schaffer PA
    J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological activity of olomoucine II.
    Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
    Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
    Ljungman M; Paulsen MT
    Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
    Peñuelas S; Alemany C; Noé V; Ciudad CJ
    Eur J Biochem; 2003 Dec; 270(24):4809-22. PubMed ID: 14653808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors.
    Korinkova G; Cwiertka K; Paprskarova M; Dzubak P; Hajduch M
    Neoplasma; 2010; 57(2):161-9. PubMed ID: 20099981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Roscovitine, a novel cyclin-dependent kinase inhibitor, characterizes restriction point and G2/M transition in tobacco BY-2 cell suspension.
    Planchais S; Glab N; Tréhin C; Perennes C; Bureau JM; Meijer L; Bergounioux C
    Plant J; 1997 Jul; 12(1):191-202. PubMed ID: 9263460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases.
    Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN
    Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
    Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
    Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases.
    Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D
    Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replication-dependent DNA damage response triggered by roscovitine induces an uncoupling of DNA replication proteins.
    Savio M; Cerri M; Cazzalini O; Perucca P; Stivala LA; Pichierri P; Franchitto A; Meijer L; Prosperi E
    Cell Cycle; 2006 Sep; 5(18):2153-9. PubMed ID: 16969115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
    Havlícek L; Hanus J; Veselý J; Leclerc S; Meijer L; Shaw G; Strnad M
    J Med Chem; 1997 Feb; 40(4):408-12. PubMed ID: 9046330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
    Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
    J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs.
    Ribas J; Boix J
    Exp Cell Res; 2004 Apr; 295(1):9-24. PubMed ID: 15051486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATP-site directed inhibitors of cyclin-dependent kinases.
    Gray N; Détivaud L; Doerig C; Meijer L
    Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.
    Pippin JW; Qu Q; Meijer L; Shankland SJ
    J Clin Invest; 1997 Nov; 100(10):2512-20. PubMed ID: 9366565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by cell cycle inhibitors.
    Wartenberg M; Fischer K; Hescheler J; Sauer H
    Biochim Biophys Acta; 2002 Feb; 1589(1):49-62. PubMed ID: 11909640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent of activation by Munc-18.
    Veeranna ; Shetty KT; Amin N; Grant P; Albers RW; Pant HC
    Neurochem Res; 1996 May; 21(5):629-36. PubMed ID: 8726973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
    Wesierska-Gadek J; Gueorguieva M; Kramer MP; Ranftler C; Sarg B; Lindner H
    J Cell Biochem; 2007 Dec; 102(6):1405-19. PubMed ID: 17975794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
    Wu PC; Tai MH; Hu DN; Lai CH; Chen YH; Wu YC; Tsai CL; Shin SJ; Kuo HK
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):25-33. PubMed ID: 18370874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical inhibitors of cyclin-dependent kinases control proliferation, apoptosis and differentiation of oligodendroglial cells.
    Nguyen L; Malgrange B; Rocher V; Hans G; Moonen G; Rigo JM; Belachew S
    Int J Dev Neurosci; 2003 Oct; 21(6):321-6. PubMed ID: 12927580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.